Respiratory Syncytial Virus Antibody (2F7)

Respiratory syncytial virus (RSV) is a negative-sense, enveloped RNA virus. The virion is variable in shape and size (average diameter of between 120 and 300 nm), is unstable in the environment (surviving only a few hours on environmental surfaces), and is readily inactivated with soap and water and disinfectants. It is the most common cause of bronchiolitis and pneumonia among infants and children under 1 year of age. Illness begins most frequently with fever, runny nose, cough, and sometimes wheezing. During their first RSV infection, between 25percent and 40percent of infants and young children have signs or symptoms of bronchiolitis or pneumonia, and 0.5percent to 2percent require hospitalization. Most children recover from illness in 8 to 15 days. The majority of children hospitalized for RSV infection are under 6 months of age. RSV also causes repeated infections throughout life, usually associated with moderate-to-severe cold-like symptoms; however, severe lower respiratory tract disease may occur at any age, especially among the elderly or among those with compromised cardiac, pulmonary, or immune systems.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 1 confirmed species: Primates.

Showing Publication 1 - 1 of 1.

Publication using NB110-37246	Applications	Species
Mueller S, Stauft CB, Kalkeri R et al. A codon-pair deoptimized live-attenuated vaccine against respiratory syncytial virus is immunogenic and efficacious in non-human primates Vaccine 2020-02-24 [PMID: 32107060] (Primates)		Primates

Array NB110-37246

• Respiratory Syncytial Virus Antibodies